Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: Role of rituximab

Zeitschrift fur Gastroenterologie

Volumn 48, Issue 2, 2010, Pages 258-263

  Stange, M A ^a   Tutarel, O ^a   Pischke, S ^a   Schneider, A ^a   Strassburg, C P ^a   Becker, T ^a   Barg Hock, H ^a   Basturk M ^a   Wursthorn, K ^a   Cornberg, M ^a   Ott, M ^a,b   Greten, T F ^a   Manns, M P ^a   Wedemeyer, Heiner ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

Author keywords

Hepatitis B; Immunosuppression; Rituximab; Transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER REGRESSION; CASE REPORT; DISEASE SEVERITY; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS B VIRUS; HEPATOCYTE TRANSPLANTATION; HUMAN; HUMAN TISSUE; JAUNDICE; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; RECURRENT INFECTION; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; CELL TRANSPLANTATION; CYCLOPHOSPHAMIDE; DOXORUBICIN; FATAL OUTCOME; HEPATITIS B; HEPATOCYTES; HUMANS; IMMUNOLOGIC FACTORS; LIVER FAILURE; LIVER TRANSPLANTATION; LYMPHOMA, B-CELL; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; PREDNISONE; STOMACH NEOPLASMS; VINCRISTINE; VIRUS ACTIVATION;

EID: 77749307226     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1109782     Document Type: Article

References (46)

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B.J Hepatol 2009; 50: in press
2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539
3. Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008; 48 (Suppl 1 ): S2-S19
4. Raimondo G, Pollicino T, Cacciola I et al. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-170
5. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 215-229
6. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136: 699-712
7. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-220
8. Yeo W, Zee B, Zhang S et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-1311
9. Cornberg M, Protzer U, Dollinger MM et al. Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. Z Gastroenterol 2007; 45: 1281-1328
10. Rosenau J, Kreutz T, Kujawa M et al. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. J Hepatol 2007; 46: 635-644
11. Schneider A, Attaran M, Meier PN et al. Hepatocyte transplantation in an acute liver failure due to mushroom poisoning. Transplantation 2006; 82: 1115-1116
12. Alexandrova K, Griesel C, Barthold M et al. Large-scale isolation of human hepatocytes for therapeutic application. Cell Transplant 2005; 14: 845-853
13. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242
14. Hui CK, Cheung WW, Zhang HY et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68
15. Rehermann B, Ferrari C, Pasquinelli C et al. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-1108
16. Menne S, Cote PJ, Butler SD et al. Immunosuppression reactivates viral replication long after resolution of woodchuck hepatitis virus infec-tion. Hepatology 2007; 45: 614-622
17. Ciesek S, Helfritz FA, Lehmann U et al. Persistence of occult hepatitis B after removal of the hepatitis B virus-infected liver. J Infect Dis 2008; 197: 355-360
18. Cahalan MD, Parker I. Close encounters of the first and second kind: T-DC and T-B interactions in the lymph node. Semin Immunol 2005; 17: 442-451
19. Tillmann HL, Hadem J, Leifeld L et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience.J Viral Hepat 2006; 13: 256-263
20. ter Borg F, Smorenburg S, de Man RA et al. Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. Dig Dis Sci 1998; 43: 2267-2270
21. Clark FL, Drummond MW, Chambers S et al. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 385-387
22. Santantonio T, Mazzola M, Pastore G. Lamivudine is safe and effective in fulminant viral hepatitis.J Hepatol 1999; 30: 551
23. Girke J, Wedemeyer H, Wiegand J et al. Acute hepatitis B: is antiviral therapy indicated? Two case reports. Dtsch Med Wochenschr 2008; 133: 1178-1182
24. Raimondo G, Pollicino T, Cacciola I et al. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-170
25. Li YH, He YF, Jiang WQ et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006; 106: 1320-1325
26. Lau GK, Yiu HH, Fong DY et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-1749
27. Shibolet O, Ilan Y, Gillis S et al. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002; 100: 391-396
28. Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int 2008; 28: 28-38
29. Katz LH, Fraser A, Gafter-Gvili A et al. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008; 15: 89-102
30. Loomba R, Rowley A, Wesley R et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-528
31. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020
32. Ott M. A symphony of techniques for liver cell therapy, only applicable to rats? J Hepatol 2008; 49: 6-8
33. Tsutsumi Y, Tanaka J, Kawamura T et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004; 83: 58-60
34. Tsutsumi Y, Kawamura T, Saitoh S et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004; 45: 627-629
35. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-69
36. Westhoff TH, Jochimsen F, Schmittel A et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930
37. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005; 11: 189-191
38. Law JK, Ho JK, Hoskins PJ et al. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46: 1085-1089
39. Sera T, Hiasa Y, Michitaka K et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006; 45: 721-724
40. Perceau G, Diris N, Estines O et al. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006; 155:1053-1056
41. Ono K, lyama S, Matsunaga T et al. Reactivation of hepatitis B virus due to rituximab plus CHOP after preemptive lamivudine administration in a patient with diffuse large B-cell lymphoma. Gan To Kagaku Ryoho 2007; 34: 1509-1512
42. Lovric S, Erdbruegger U, Kümpers P et al. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: single centre experience with 15 patients. Nephrol Dial Transplant 2009; 24: 179-185
43. Hernandez JA Diloy R, Salat D et al. Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab. Haematologica 2003; 88: ECR22
44. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-276
45. Ng HJ, Lim LC. Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann Hematol 2001; 80: 549-552
46. Skrabs C, Müller C, Agis H et al. Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia 2002; 16: 1884-1886